ContextIn the Trilège trial, following induction with a zidovudine, lamivudine, and indinavir
regimen, human immunodeficiency virus (HIV) replication was less suppressed by 2-drug …

Background The long-term effectiveness of potent three-drug antiretroviral regimens for the
treatment of human immunodeficiency virus type 1 (HIV-1) infection is limited by problems …

ContextLoss of viral suppression in patients infected with human immunodeficiency virus
(HIV), who are receiving potent antiretroviral therapy, has been attributed to outgrowth of …

Background Combination antiretroviral therapy with indinavir, zidovudine, and lamivudine
can suppress the level of human immunodeficiency virus (HIV) RNA in plasma below the …

Context.—Combination antiretroviral therapy can markedly suppress human
immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among …

Twenty human immunodeficiency virus—infected patients experiencing virologic failure of
an indinavir-or ritonavir-containing treatment regimen were evaluated in a prospective, open …

Background It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1)
should be initiated with a four-drug or two sequential three-drug regimens. Methods In this …

This study's hypothesis is that human immunodeficiency virus—infected patients in the inner
city (predominantly injection drug users and ethnic minorities) do not take highly active …

Background The optimal sequencing of antiretroviral regimens for the treatment of infection
with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several …

This randomized study evaluated the efficacy and tolerability of continued treatment with
protease inhibitor plus nucleoside-analogue combination regimens (n= 79) or a change to …